/
CABA
$3.11+$0.07 (+2.30%)live
Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
1
institution
Market cap
$495.7M
163M shares
52-week range
$1.26 – $4.23
62% from low
Sector
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Exchange
NASDAQ
CS
Borrow rate
0.45%
Easy to borrow
Price (6 mo)
Loading chart…
Change$-5.49
Valuation
Financials
Loading chart…
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Cost of revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Gross profit | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Gross margin | — | — | — | — | — | — | — | — |
| R&D | $4.5M | $11.7M | $21.4M | $32.5M | $39.3M | $55.4M | $97.2M | $142.7M |
| Operating income | −$6.2M | −$18.7M | −$33.8M | −$46.3M | −$54.1M | −$74.7M | −$125.1M | −$172.2M |
| EBITDA | −$6.0M | −$18.6M | −$33.0M | −$45.6M | −$51.8M | −$66.2M | −$113.4M | −$164.2M |
| Net income | −$12.2M | −$16.9M | −$33.3M | −$46.3M | −$53.0M | −$67.7M | −$115.9M | −$167.9M |
| Net margin | — | — | — | — | — | — | — | — |
| EPS (diluted) | -0.84 | -4.07 | -1.44 | -1.80 | -1.81 | -1.65 | -2.34 | -1.64 |
Annual figures · source: Financial Modeling Prep
Analyst estimates (consensus)
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $3M | $-1.37 | $-1.62–$-0.99 | 5 |
| 2027 | $712586 | $-1.24 | $-1.45–$-1.02 | 4 |
| 2028 | $64M | $-1.14 | $-2.43–$-0.47 | 7 |
| 2029 | $346M | $-0.65 | $-0.65–$-0.65 | 2 |
Forward consensus · source: Financial Modeling Prep
DCF fair valuemodel estimate
Intrinsic value
$0.49
Price
$3.11
Implied downside
-84%
Peer comparison
Cabaletta Bio, Inc. Common Stock
Cabaletta Bio Inc is a late clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies for autoimmune diseases. Its proprietary Cabaletta Approach to B cell Ablation (CABA) platform includes the CARTA approach, which uses chimeric antigen receptor T cells to eliminate B cells and potentially reset the immune system. The company develops cellular therapies including CAR T and CAAR T product candidates. Its candidate, rese-cel (resecabtagene autoleucel), a CD19-CAR T cell therapy, is being evaluated in Phase 1/2 trials for autoimmune diseases such as systemic lupus erythematosus, myositis, systemic sclerosis, generalized myasthenia gravis, and pemphigus vulgaris.
www.cabalettabio.com- Employees
- 158
- IPO / List date
- Oct 25, 2019
- HQ
- PHILADELPHIA, PA
Held by traders on TradeandTell
No one on the platform currently holds CABA.
Super investors & insiders
Institutions holding (13F)
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2026-03-31 | 2,036,663 | $5.5M |
Insider activity (SEC Form 4)
Recent trades on TradeandTell
No one on the platform has traded CABA yet.
